SGI
CSTL icon

Summit Global Investments’s Castle Biosciences CSTL Stock Holding History

Summit Global Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Sell
13,078
-640
-5% -$14.3K 0.02% 442
2026
Q1 		$337K Buy
13,718
+1,353
+11% +$44.3K 0.02% 397
2025
Q4 		$481K Buy
12,365
+13
+0.1% +$419 0.03% 325
2025
Q3 		$281K Sell
12,352
-3,297
-21% -$67K 0.02% 406
2025
Q2 		$320K Sell
15,649
-14,991
-49% -$278K 0.02% 381
2025
Q1 		$613K Buy
30,640
+2,164
+8% +$53.6K 0.04% 261
2024
Q4 		$759K Sell
28,476
-1,965
-6% -$59.8K 0.05% 272
2024
Q3 		$868K Buy
30,441
+6,629
+28% +$169K 0.06% 259
2024
Q2 		$518K Buy
+23,812
New +$531K 0.03% 339

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Global Investments's CSTL Position: Q2 2026 in Review

Summit Global Investments reduced its Castle Biosciences (CSTL) stake by 4.7% in Q2 2026, selling an estimated $14.3K and leaving 13,078 shares worth $312K. The position accounts for 0.02% of the portfolio, ranked #442.

Summit Global Investments first reported a position in CSTL in Q2 2024 and has held it in 9 quarters since. The position peaked at $868K in Q3 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Summit Global Investments held 13,078 shares of Castle Biosciences worth $312K as of Q2 2026.
  • Summit Global Investments sold 640 Castle Biosciences shares in Q2 2026, an estimated $14.3K.
  • Castle Biosciences made up 0.02% of Summit Global Investments's portfolio in Q2 2026, its #442 holding.
  • Summit Global Investments first reported a position in Castle Biosciences in Q2 2024 and has held it in 9 quarters since.
  • Summit Global Investments's Castle Biosciences position peaked at $868K in Q3 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.